Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis
Author: ["Daewoong Jo","Danya Liu","Shan Yao","Robert D Collins","Jacek Hawiger"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Suppressor of cytokine signaling (SOCS) 3 attenuates proinflammatory signaling mediated by the signal transducer and activator of transcription (STAT) family of proteins. But acute inflammation can occur after exposure to pathogen-derived inducers staphylococcal enterotoxin B (SEB) and lipopolysaccharide (LPS), or the lectin concanavalin A (ConA), suggesting that physiologic levels of SOCS3 are insufficient to stem proinflammatory signaling under pathogenic circumstances. To test this hypothesis, we developed recombinant cell-penetrating forms of SOCS3 (CP-SOCS3) for intracellular delivery to counteract SEB-, LPS- and ConA-induced inflammation. We found that CP-SOCS3 was distributed in multiple organs within 2 h and persisted for at least 8 h in leukocytes and lymphocytes. CP-SOCS3 protected animals from lethal effects of SEB and LPS by reducing production of inflammatory cytokines and attenuating liver apoptosis and hemorrhagic necrosis. It also reduced ConA-induced liver apoptosis. Thus, replenishing the intracellular stores of SOCS3 with CP-SOCS3 effectively suppresses the devastating effects of acute inflammation.
Cite this article
Jo, D., Liu, D., Yao, S. et al. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 11, 892–898 (2005). https://doi.org/10.1038/nm1269